Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxabact extension in primary hyperoxaluria
NCT03938272Phase 3Terminated
- Sponsor
- OxThera AB
- Start
- Mar 2019
- Primary completion
- Jul 2021
- Modality
- Live Biotherapeutic Products
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of oxalobacter formigenes in Primary hyperoxaluria (PH), sponsored by OxThera AB. Primary endpoint: Change From Baseline in Kidney Function (eGFR) at 24 months. Started Mar 2019; status: terminated.
02
Drugs
oxalobacter formigenes
03
Conditions
Primary hyperoxaluria (PH)
Beyond the preview
Go deeper on NCT03938272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03938272.